Lupengbio
3 known investors
Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
Founders & leadership
周
周正清首席财务官 (CFO)
SA
Stephen Anthony首席医学官 (Chief Medical Officer)
Investors · 3
Frequently asked questions
- What does Lupengbio do?
- Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
- Who are Lupengbio's investors?
- Lupengbio's investors include LAV, Lilly Asia Ventures, OrbiMed.